11.13.20
6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Sign-up for the newsletter for access.

It's a good one, too.

This article is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

×

Newsletters

Filter by
All Selling to Employers Prescription Digital Therapeutics National Virtual Clinics
    425 articles
  • First
  • Previous
    • 1 of 43
  • Next
  • Last
Oura subscription revs, rings sold, hardware margin. New ACCESS Model participants
6.05.26
7 min. Read
Six years of Oura’s financials: Revenue, profits, marketing spend and more
5.22.26
4 min. Read
ACCESS Model’s first dropout? Plus: A few new participants
5.08.26
6 min. Read
Are these Utah’s next four AI experiments? Plus: More on the Utah Pharmacy Board’s questions about Doctronic
4.17.26
9 min. Read
Emails show how Doctronic’s AI pilot blindsided Utah’s Medical Board
4.10.26
13 min. Read
Quiet funding rounds. Plus: Digital health-related clinical trial round-ups
3.20.26
5 min. Read
Details: Vida Health’s brief GLP-1 rollout in Mass. Plus: CMS says Freespira not DME
3.13.26
7 min. Read
AI billing codes for 5-min visits? Cityblock $1.5B ARR.
2.27.26
8 min. Read
K Health shuts down DTC clinic. Big employer customer wins, losses
2.20.26
6 min. Read
ACCESS Model’s shockingly low payments. DMHT Rx count.
2.13.26
7 min. Read
  • First
  • Previous
    • 1 of 43
  • Next
  • Last